|
Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma |
Raimundo K, Biskupiak J, Goodman M, Silverstein S, Asche C |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Raimundo K, Biskupiak J, Goodman M, Silverstein S, Asche C. Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma. Journal of Medical Economics 2013; 16(5): 606-613 Indexing Status Subject indexing assigned by NLM MeSH AIDS-Related Opportunistic Infections /drug therapy; Antineoplastic Agents /administration & Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Trees; Doxorubicin /administration & Humans; Liposomes; Paclitaxel /economics /therapeutic use; Sarcoma, Kaposi /drug therapy; dosage /economics /therapeutic use; dosage /economics /therapeutic use AccessionNumber 22013027272 Date bibliographic record published 01/08/2013 |
|
|
|